NuCana PLC
NCNA3.560USD
+0.090+2.59%
收盘 12/19, 16:00（美东）报价延迟15分钟
5.11B总市值
0.01市盈率 TTM
关于 NuCana PLC 公司
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.
NuCana PLC简介
公司代码NCNA
公司名称NuCana PLC
上市日期Sep 28, 2017
CEO- -
员工数量20
证券类型Depository Receipt
年结日Sep 28
公司地址Lochside House
城市EDINBURGH
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United Kingdom
邮编EH12 9DT
电话4401313571111
网址https://www.nucana.com/
公司代码NCNA
上市日期Sep 28, 2017
CEO- -
NuCana PLC公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Non-Executive Independent Director
Non-Executive Independent Director
22.00
--
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
7.00
+16.67%
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
4.00
+300.00%
Dr. Jeffrey D. Bloss, M.D.
Dr. Jeffrey D. Bloss, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew Kay
Mr. Andrew Kay
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Cyrille Leperlier, M.D.
Dr. Cyrille Leperlier, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Christopher F. Brinzey
Mr. Christopher F. Brinzey
Investor Relations
Investor Relations
--
--
Dr. David Harrison, M.D.
Dr. David Harrison, M.D.
Head - Translational Studies
Head - Translational Studies
--
--
Mr. Ian Webster
Mr. Ian Webster
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Non-Executive Independent Director
Non-Executive Independent Director
22.00
--
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
7.00
+16.67%
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
4.00
+300.00%
Dr. Jeffrey D. Bloss, M.D.
Dr. Jeffrey D. Bloss, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew Kay
Mr. Andrew Kay
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Cyrille Leperlier, M.D.
Dr. Cyrille Leperlier, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 12月17日 周三
更新时间: 12月17日 周三
持股股东
股东类型
持股股东
持股股东
占比
Abingworth Management Limited
1.86%
Glass Jacobson Wealth Advisors
0.21%
Jane Street Capital, L.L.C.
0.18%
UBS Financial Services, Inc.
0.14%
Global Retirement Partners, LLC
0.06%
其他
97.55%
持股股东
持股股东
占比
Abingworth Management Limited
1.86%
Glass Jacobson Wealth Advisors
0.21%
Jane Street Capital, L.L.C.
0.18%
UBS Financial Services, Inc.
0.14%
Global Retirement Partners, LLC
0.06%
其他
97.55%
股东类型
持股股东
占比
Venture Capital
1.87%
Investment Advisor
0.42%
Research Firm
0.18%
Hedge Fund
0.02%
其他
97.52%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
49
156.10K
8.18%
+152.88K
2025Q2
52
554.99K
0.15%
+48.75K
2025Q1
52
492.36K
2.30%
-26.46K
2024Q4
52
469.91K
11.91%
+42.72K
2024Q3
52
279.81K
7.09%
-247.00K
2024Q2
51
362.89K
15.79%
-1.48K
2024Q1
59
340.51K
14.80%
-343.96K
2023Q4
65
549.25K
25.71%
-320.80K
2023Q3
68
668.24K
31.65%
-112.66K
2023Q2
71
571.34K
27.26%
-362.30K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Abingworth Management Limited
667.00
0.04%
--
--
Jun 30, 2025
Glass Jacobson Wealth Advisors
75.00
0%
--
--
Jun 30, 2025
Sofinnova Investments, Inc
998.00
0.05%
+998.00
--
Feb 14, 2025
Rhumbline Advisers Ltd. Partnership
40.00
0%
+31.00
+344.44%
Jun 30, 2025
Griffith (Hugh S)
53.00
0%
--
--
Dec 31, 2024
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Jul 11, 2025
Merger
200→1
Apr 12, 2024
Merger
25→1
Apr 12, 2024
Merger
25→1
Apr 12, 2024
Merger
25→1
Apr 12, 2024
Merger
25→1
公告日期
类型
比率
Jul 11, 2025
Merger
200→1
Apr 12, 2024
Merger
25→1
Apr 12, 2024
Merger
25→1
Apr 12, 2024
Merger
25→1
Apr 12, 2024
Merger
25→1
常见问题
NuCana PLC的前五大股东是谁？
NuCana PLC 的前五大股东如下：
Abingworth Management Limited持有股份：667.00，占总股份比例：0.04%。
Glass Jacobson Wealth Advisors持有股份：75.00，占总股份比例：0.00%。
Sofinnova Investments, Inc持有股份：998.00，占总股份比例：0.05%。
Rhumbline Advisers Ltd. Partnership持有股份：40.00，占总股份比例：0.00%。
Griffith (Hugh S)持有股份：53.00，占总股份比例：0.00%。
Abingworth Management Limited持有股份：667.00，占总股份比例：0.04%。
Glass Jacobson Wealth Advisors持有股份：75.00，占总股份比例：0.00%。
Sofinnova Investments, Inc持有股份：998.00，占总股份比例：0.05%。
Rhumbline Advisers Ltd. Partnership持有股份：40.00，占总股份比例：0.00%。
Griffith (Hugh S)持有股份：53.00，占总股份比例：0.00%。
NuCana PLC的前三大股东类型是什么？
NuCana PLC 的前三大股东类型分别是：
Abingworth Management Limited
Glass Jacobson Wealth Advisors
Jane Street Capital, L.L.C.
Abingworth Management Limited
Glass Jacobson Wealth Advisors
Jane Street Capital, L.L.C.
有多少机构持有NuCana PLC(NCNA)的股份？
截至2025Q3，共有49家机构持有NuCana PLC的股份，合计持有的股份价值约为156.10K，占公司总股份的8.18%。与2025Q2相比，机构持股有所增加，增幅为8.04%。
哪个业务部门对NuCana PLC的收入贡献最大？
在--，--业务部门对NuCana PLC的收入贡献最大，创收--，占总收入的--%。
